The success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07).
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine.
Aclarion is a startup launched by UCSF based on the technologies developed by Dr. Jeffrey Lotz.